XXXX and Insulin Therapy, but Not @entity2449 , Are Related to Hepatocellular Cancer Risk.

@entity1 @entity286 @entity6 @entity5736 @entity157 @entity2449
Introduction. Metabolic conditions, including type 2 @entity6 , have been related to @entity157 ( @entity157 ) risk. We have further analyzed the role of @entity6 and antidiabetic treatments on @entity157 . Methods. Data derived from a hospital-based case-control study (Italy, 2005-2012) on 224 @entity157 @entity1 and 389 controls. Odds ratios (ORs) were estimated using multiple logistic regression models. Results. Sixty-nine (30.9%) cases versus 52 (13.5%) controls reported a @entity6 diagnosis, corresponding to a multivariate OR of 2.25 (95% confidence interval, CI = 1.42-3.56). A stronger excess risk emerged for a longer time since @entity6 diagnosis (OR = 2.96 for <10 years and 5.33 for >= 10 years). Oral therapies were inversely, though not significantly, related to @entity157 risk, OR being 0.44 for @entity2449 and 0.88 for @entity5736 ; conversely, insulin was nonsignificantly directly associated (OR = 1.90). Compared to nondiabetic subjects who were never smokers, those who were @entity6 and ever smokers had an OR of 6.61 (95% CI 3.31-13.25). Conclusion. Our study confirms an over 2-fold excess @entity157 risk in @entity6 , with a stronger excess risk in @entity6 subjects who are also @entity286 smokers. @entity2449 may decrease the risk of @entity157 , whereas insulin may increase the risk.
